"In addition to statistically significant changes in immune cells, there was a statistically significant reductionin the level of the macrophageactivation marker sCD163 in the blood of the BIT225-treated cohort by theend of the treatment period compared to the placebo group in the trial".
"The additional data currently being generated bythe Company on characterising the mechanism of action of BIT225 seen in the results of the BIT225-009trial are valuable to furthering these discussions.". Skeptic in me believes this will be released prior to option expiry.
"While Biotron’swork on its HBV compounds is preclinical, the data from these recent studies further validate Biotron’sapproach to antiviral drug development and may provide the Company with an early stage developmentopportunity with an appropriate partner."
Cash - $5.8m
Cons -
There was no real additional information and no update on the discussion with experts which was supposed to happen a few weeks after the 11th of July. "No matters or circumstances have arisen since the end of the financial year which significantly affected ormay significantly affect the operations of the Company, the results of those operations, or the state of affairsof the Company in future financial years."
Sorry I don't have any real analysis of value on the announcement.
Would love to hear others thoughts on the report (including Dav)
BIT Price at posting:
7.5¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)